Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China (Recruiting) - 11 Jun `26D-2570 tablets for nonsegmental vitiligo

D-2570 tablets for nonsegmental vitiligo

Official title: A Phase 2 Multicenter, Randomized, Parallel-group, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of D-2570 in Subjects With Non-Segmental Vitiligo

Status: Recruiting now

Description:

InventisBio Co., Ltd plans to enroll about 160 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 65 may qualify. The study is recruiting at one listed site in China.

Start date: June 11, 2026

Completion date: May 01, 2028

Organizer: InventisBio Co., Ltd

Contact: shilin Sha

Tel.: 1 560 182 667 8

Email: shilin.sha@inventisbio.com

Link: https://clinicaltrials.gov/study/NCT07625891

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference D-2570 tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Is it Bitiligo? Vitaligo? Veteligo?

    There are so many different ways that people try and spell or even pronounce Vitiligo. Here are some common mis-spellings: bitiligo, vitigo, vitaligo, vitilago, vitiglio, vitag...

  • I have vitiligo: will my children have vitiligo, too?

    If you have vitiligo, it’s natural to worry about your children. While there is a genetic component, vitiligo is not a straightforward hereditary disease like eye color or heigh...

  • Can Ayurveda help with vitiligo?

    Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...